These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30397707)

  • 1. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism.
    Zhang LY; Gao BA; Jin Z; Xiang GM; Gong Z; Zhang TT; Lu HF; Wang YQ; Gong Y; Lu C; Huang WL
    Saudi Med J; 2018 Nov; 39(11):1090-1095. PubMed ID: 30397707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose thrombolysis for submassive pulmonary embolism.
    Yilmaz ES; Uzun O
    J Investig Med; 2021 Dec; 69(8):1439-1446. PubMed ID: 34099544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism.
    Kucher N; Boekstegers P; Müller OJ; Kupatt C; Beyer-Westendorf J; Heitzer T; Tebbe U; Horstkotte J; Müller R; Blessing E; Greif M; Lange P; Hoffmann RT; Werth S; Barmeyer A; Härtel D; Grünwald H; Empen K; Baumgartner I
    Circulation; 2014 Jan; 129(4):479-86. PubMed ID: 24226805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism.
    Güner A; Kalçik M; Aykan AÇ; Gürsoy MO; Kalkan AK; Astarcioğlu MA; Ertürk M; Uzun F; Güner EG; Yildiz M; Özkan M
    Blood Coagul Fibrinolysis; 2020 Dec; 31(8):536-542. PubMed ID: 33181758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism.
    Sharifi M; Awdisho A; Schroeder B; Jiménez J; Iyer P; Bay C
    Vasc Med; 2019 Apr; 24(2):103-109. PubMed ID: 30834822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis.
    Li HY; Wang YB; Ren XY; Wang J; Wang HS; Jin YH
    Pharmacology; 2023; 108(2):111-126. PubMed ID: 36603558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism.
    Bagla S; Smirniotopoulos JB; van Breda A; Sheridan MJ; Sterling KM
    J Vasc Interv Radiol; 2015 Jul; 26(7):1001-6. PubMed ID: 25704224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis with reteplase in acute pulmonary embolism.
    Nishanth KR; Math RS; Shankar M; Ravindranath KS; Manjunath CN
    Indian Heart J; 2019; 71(6):464-467. PubMed ID: 32248919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study.
    Piazza G; Hohlfelder B; Jaff MR; Ouriel K; Engelhardt TC; Sterling KM; Jones NJ; Gurley JC; Bhatheja R; Kennedy RJ; Goswami N; Natarajan K; Rundback J; Sadiq IR; Liu SK; Bhalla N; Raja ML; Weinstock BS; Cynamon J; Elmasri FF; Garcia MJ; Kumar M; Ayerdi J; Soukas P; Kuo W; Liu PY; Goldhaber SZ;
    JACC Cardiovasc Interv; 2015 Aug; 8(10):1382-1392. PubMed ID: 26315743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism.
    Harvey JJ; Huang S; Uberoi R
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD013083. PubMed ID: 35938605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of low-dose tissue plasminogen activator therapy in acute pulmonary embolism.
    Hezer H; Kiliç H; Abuzaina O; Hasanoǧlu HC; Karalezli A
    J Investig Med; 2019 Dec; 67(8):1142-1147. PubMed ID: 31341000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.
    Wang C; Zhai Z; Yang Y; Wu Q; Cheng Z; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH;
    Chest; 2010 Feb; 137(2):254-62. PubMed ID: 19741062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy of acute pulmonary embolism: current status and future potential.
    Goldhaber SZ; Meyerovitz MF; Markis JE; Kim D; Kessler CM; Sharma GV; Vaughan DE; Selwyn AP; Dawley DL; Loscalzo J
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):96B-104B. PubMed ID: 3117862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism].
    Li ZP; Xu B; Jiang R; Li JL; Jiang X; Sun ML; Jing ZC; Li YP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):224-8. PubMed ID: 23879948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.
    Zhang Z; Zhai ZG; Liang LR; Liu FF; Yang YH; Wang C
    Thromb Res; 2014 Mar; 133(3):357-63. PubMed ID: 24412030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and safety of thrombolytic treatment with reteplase in patients with intermediate-risk acute pulmonary embolism].
    Zhao HG; Wang SX; Lu ZN; Yan XX; Lyu ZC; Peng FH; Wu Y; Gao X; Hua L; Jing ZC; Xu XQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Apr; 45(4):314-317. PubMed ID: 28545283
    [No Abstract]   [Full Text] [Related]  

  • 17. Transforming and simplifying the treatment of pulmonary embolism: "safe dose" thrombolysis plus new oral anticoagulants.
    Sharifi M; Vajo Z; Freeman W; Bay C; Sharifi M; Schwartz F
    Lung; 2015 Jun; 193(3):369-74. PubMed ID: 25749665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial.
    Sanchez O; Charles-Nelson A; Ageno W; Barco S; Binder H; Chatellier G; Duerschmied D; Empen K; Ferreira M; Girard P; Huisman MV; Jiménez D; Katsahian S; Kozak M; Lankeit M; Meneveau N; Pruszczyk P; Petris A; Righini M; Rosenkranz S; Schellong S; Stefanovic B; Verhamme P; de Wit K; Vicaut E; Zirlik A; Konstantinides SV; Meyer G;
    Thromb Haemost; 2022 May; 122(5):857-866. PubMed ID: 34560806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of Cardiopulmonary Function in Patients Treated with Ultrasound-Accelerated Thrombolysis in the Setting of Submassive Pulmonary Embolism.
    Knox MF; Langholz DE; Berjaoui WK; Eberhart L
    J Vasc Interv Radiol; 2019 May; 30(5):734-741. PubMed ID: 30857985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-accelerated thrombolysis (USAT) versus standard catheter-directed thrombolysis (CDT) for treatment of pulmonary embolism: A retrospective analysis.
    Rothschild DP; Goldstein JA; Ciacci J; Bowers TR
    Vasc Med; 2019 Jun; 24(3):234-240. PubMed ID: 30915912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.